Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.40 |
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | HTR1A | P08908 | 4/20 | 0.40 |
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | MPO | P05164 | 3/20 | 0.40 |
| ▸ | HTR1D | P28221 | 6/20 | 0.39 |
| ▸ | HTR1B | P28222 | 5/20 | 0.39 |
| ▸ | HTR2B | P41595 | 4/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.39 |
| ▸ | HTR3B | O95264 | 2/20 | 0.39 |
| ▸ | HTR1E | P28566 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12016746 | 0.87 | HTR1A (0.56) | CYP2D6KMT2ASLC6A4HTR2AHTR1A | |
| SCHEMBL1337645 | 0.85 | LPL (0.42) | HTR2AHTR1AMPOHTR1DHTR1B | |
| SCHEMBL1337282 | 0.83 | LPL (0.50) | HTR2AHTR1AMPOHTR1DHTR1B | |
| SCHEMBL15897087 | 0.80 | ALDH1A1 (0.56) | KDM4EMEN1ALDH1A1TSHRCYP2C19 | |
| SCHEMBL25776268 | 0.79 | LPL (0.37) | HTR1AMPOHTR1DHTR1BLPL | |
| SCHEMBL1337551 | 0.77 | ATM (0.41) | LPLLIPG | |
| SCHEMBL27159868 | 0.75 | KDM4E (0.47) | KDM4EMEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL27159932 | 0.75 | LPL (0.46) | KDM4EMEN1ALDH1A1KMT2ASLC6A4 | |
| SCHEMBL15912503 | 0.74 | LPL (0.42) | HTR2ALPLLIPG | |
| SCHEMBL22438423 | 0.74 | LPL (0.38) | HTR2AHTR2CHTR2BLPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | CYP2D6 23/4885KDM4E 3676/4885MEN1 878/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | CYP2D6 23/4885KDM4E 3676/4885MEN1 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.